What is Relay Therapeutics, Inc.'s deferred revenue?

Relay Therapeutics, Inc. (RLAY) reported deferred revenue of -$7.68M in Q1 2025.

How has Relay Therapeutics, Inc.'s deferred revenue changed year-over-year?

Relay Therapeutics, Inc.'s deferred revenue decreased by 500.0% year-over-year, from $1.92M to -$7.68M.

Relay Therapeutics, Inc. RLAY Deferred Revenue

Deferred Revenue at other companies

Tango TherapeuticsTNGX

——

BridgeBio PharmaBBIO

——

Rhythm Pharmaceuticals, Inc.RYTM

——

Other financials

Income statement

See full

Revenue$3.0M-60.9%

Operating income-$78.6M+7.4%

Net income-$73.3M+4.9%

EPS (diluted)-$0.41+10.9%

Balance sheet

See full

Cash & equivalents$204.6M+119%

Total debt$31.6M-33.1%

Total equity$642.2M-10.9%

Total assets$699.6M-12.5%

Cash flow

See full

Operating cash flow-$51.1M+30.2%

CapEx$1.0K—

Free cash flow-$44.9M+22.5%

Valuation

See full

Market cap$3.8B+300%

Profitability

See full

Operating margin-2,776.6%-820pp

Net margin-2,554.1%-745pp

FCF margin-1,536%-429pp

Returns & leverage

See full

Return on equity-40%-4.3pp

Debt / equity0×0.0×

Current ratio22.1×+2.2×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s deferred revenue?: Relay Therapeutics, Inc. (RLAY) reported deferred revenue of -$7.68M in Q1 2025.
How has Relay Therapeutics, Inc.'s deferred revenue changed year-over-year?: Relay Therapeutics, Inc.'s deferred revenue decreased by 500.0% year-over-year, from $1.92M to -$7.68M.